In this study, vitamin C was administered at various times as a sour stimulant to thyroid cancer patients, and the effect on salivary absorbed dose of therapeutic radioiodine ( 131 I) was investigated. Methods: Patients with differentiated thyroid cancer who had been prepared for thyroid remnant ablation after total thyroidectomy were prospectively recruited and, using a randomnumber table, were divided into 4 groups. In the hypothyroid condition, the patients in groups A, B, C, and D began sucking vitamin C (100 mg every 4 h in the daytime over 6 d) at 1, 5, 13, and 25 h, respectively, after receiving 3.7 GBq of 131 I. Scintigraphic images of the head and neck were serially acquired after 131 I administration to assess biokinetics in the salivary glands. Calculation of salivary absorbed dose was based on the MIRD schema of the Society of Nuclear Medicine. Results: Seventytwo patients (18, 18, 19 , and 17 patients from groups A, B, C, and D, respectively) were eligible for the analysis of salivary dosimetry. Differences in absorbed doses to the parotid salivary gland (0.18 6 0.11, 0.16 6 0.07, 0.16 6 0.09, and 0.16 6 0.12 mGy/MBq in groups A, B, C, and D, respectively; P 5 0.37) and submandibular salivary gland (0.19 6 0.05, 0.17 6 0.05, 0.18 6 0.07, and 0.17 6 0.06 mGy/MBq, respectively; P 5 0.28) were not statistically significant among groups. Salivary cumulated activities arising from the first 24 h after 131 I administration accounted for 86.08% 6 7.89% (range, 75%298%) of total cumulated activities. Differences in salivary absorbed dose during the first 24 h were not statistically significant among the 4 groups either (P 5 0.32 and 0.24, respectively, for the parotid and submandibular salivary glands). Conclusion: Salivary stimulation with vitamin C at any time after 131 I administration has only a limited effect on salivary absorbed dose in thyroid cancer patients.
The radioiodine ( 131 I) used to treat thyroid cancer patients is taken up not only by thyroid tissue but also by the salivary glands because both have similar sodium iodine symporters (1, 2) . Consequently, b-radiation from 131 I exerts cytotoxic effects in the salivary glands. Salivary glands are highly radiosensitive (3) . Radiation sialadenitis and xerostomia have become the most frequent complication of high-activity 131 I therapy for thyroid cancer (2, (4) (5) (6) (7) (8) (9) . Additionally, salivary gland injury can be observed even when the administered 131 I activity is relatively low (7) (8) (9) . Recent reviews of adverse salivary effects after 131 I therapy have indicated an incidence of acute sialadenitis ranging from 24% to 67%, with chronic sialadenitis in 11%243% of those treated (2, 8, 9) . Clinically relevant xerostomia, with dry mouth, swallowing difficulties, and a loss of taste, has, to a certain extent, impaired the quality of life of thyroid cancer patients (2, (4) (5) (6) (7) (8) (9) . Therefore, prevention of salivary gland injury in 131 I therapy becomes an important issue.
The use of sour stimulation after administration of 131 I, such as ascorbic acid (vitamin C) stimulation, which can increase the flow of saliva and accelerate 131 I washout from salivary glands, has always been presumed helpful in preventing salivary gland injury in 131 I therapy. Yet, no established evidence has demonstrated that sour stimulation actually reduces salivary gland injury after 131 I therapy. Moreover, the optimal regimen of sour stimulation in 131 I therapy is still a subject of ongoing debate (10) (11) (12) (13) (14) (15) (16) .
To date, published data involving salivary gland injury and the effects of protective measures have largely been based on short-and long-term follow-up, and few studies have evaluated the effects of these protective measures from the perspective of internal radiation dosimetry. As is well recognized, normal-tissue radiation-absorbed dose delivered by an administered radiopharmaceutical correlates with attendant tissue toxicity (17) (18) (19) . Dosimetry is thus important both for determining the limit beyond which administered radiation would cause harmful side effects and for enabling assessment of the effects of various protective measures.
The objective of this prospective, randomized, singleblind, controlled study was to administer vitamin C at various times as a sour stimulant to thyroid cancer patients and investigate the effect on salivary absorbed dose of therapeutic 131 I.
MATERIALS AND METHODS

Patient Population
To be included in the study, patients had to be at least 18 y old, have a case of recently diagnosed differentiated papillary or follicular thyroid cancer, have undergone total thyroidectomy, and have been referred to the Department of Nuclear Medicine, West China Hospital, for ablation of remnant thyroid tissue, stage pT1-T3, N0-N1, M0. For women of childbearing potential, a negative result on serum human chorionic gonadotropin pregnancy testing was required.
The exclusion criteria were the presence of distant metastases; a previous history of salivary gland disorders, collagen tissue disease, diabetes, previous 131 I therapy, or external radiation to the head or neck; or difficulty drinking a large amount of water.
The study was approved by the institutional review board, and written informed consent was obtained from patients before they enrolled.
Study Design
The study was prospective, randomized, single-blind, and controlled.
Patients were divided into 4 groups by means of a randomnumber table. While in the hypothyroid condition, all patients were treated with 3.7 GBq (100 mCi) of 131 I at 4-6 wk after thyroidectomy without preceding diagnostic scanning and after maintaining a low-iodine diet for 2 wk. Levothyroxine therapy was initiated after the last salivary dosimetric measurements.
Patients in groups A, B, C, and D were instructed to start sucking vitamin C at 1, 5, 13, and 25 h, respectively, after ingestion of 131 I, 100 mg every 4 h for 6 d, the common dose used in our department. The exact timing for the sucking of vitamin C in each group is illustrated in Figure 1 .
During the study (6 d after ingestion of 131 I), all patients were required to stop taking lemon candy, gum, or any other sialogogues except for the study-associated sucking of vitamin C. Anticholinergic or antidepressant medications were temporarily discontinued if patients had been taking them before the study. All patients received 10 mg of prednisone every 8 h and ingested at least 3,000 mL of nondairy liquid daily.
Salivary Gland Dosimetry
Scintigraphy. Serial planar images of the head and neck were obtained on a dual-head g-camera (Skylight; Philips) equipped with a set of high-energy parallel-hole collimators. Salivary absorbed dose was estimated from conjugate (anterior and posterior) counts of the salivary glands in these images. Before each patient was imaged, dead-time correction was made, when necessary, to allow for high counting rates (20) . Patients were placed supine in Waters' position. Detectors were positioned to cover an area from the brain to the level of the thyroid gland. The time points, chosen from pilot studies, were 1, 2, 3, 4, 5, 13, 25, and 48 h after 131 I ingestion. Each 20-min imaging study was performed using a peak of 364 keV, a 20% window, two 10% windows on either side to allow for triple-energy window scatter correction (21) , and a 128 · 128 matrix. Elliptic regions of interest covering the parotid and submandibular salivary glands were marked on the 1-h anterior images and then flipped to the posterior images and copied to the corresponding later scans. The cerebrum was selected for background subtraction (22) . All images were reviewed by one physician who was unaware of any information about the patient.
Residence Time. The following equation was used for calculating salivary activity (A) (21):
where I A and I P are the number of counts on the salivary region of interest in the anterior and posterior images, respectively, after correcting for scatter, dead time, and background. Buijs' background correction method was applied (23) , where the anteriorposterior thickness of the body across the salivary gland and the salivary gland itself were measured on the CT scanner (Brilliance; Philips), m e is the linear attenuation coefficient (0.11/cm), t is the body anterior-posterior thickness across the salivary gland, f is the salivary self-absorption coefficient (1), and C is the camera calibration factor (43 cps/MBq). The time-activity curves used to calculate salivary residence times were fit by minimizing x 2 . The activities beyond 48 h were small, and their contribution to the cumulated activities (,1%) could be neglected (22) .
Absorbed Dose. It was assumed that all nonpenetrating radiation of 131 I deposited in the salivary glands would be completely absorbed by the glands and that all penetrating radiation would have no contribution to salivary absorbed dose. Based on the MIRD schema, salivary absorbed dose (D) was calculated as follows:
where A 0 is the administered 131 I activity (3.7 GBq), t is the salivary residence time, D is the equilibrium dose constant for nonpenetrating radiation of 131 I (0.11 GyÁg/MBqÁh), and m is the salivary gland mass (g). The masses of the salivary glands were determined by CT. The cylindric model for the parotid glands and the ellipsoid model for the submandibular glands were applied to determine the salivary FIGURE 1. Timing of start of vitamin C stimulation for each group. Ingestion of 131 I was almost always at 5 PM for all patients. Groups A and B began sucking vitamin C at 6 PM and 10 PM, respectively, on day of 131 I ingestion. Groups C and D began sucking vitamin C at 6 AM and 6 PM, respectively, on second day of 131 I ingestion. Because of nocturnal rest, no patients sucked vitamin C from 2 AM to 6 AM.
Statistics
Categoric variables were described as frequencies. Continuous variables were described as mean 6 SD. The x 2 test was used to compare the difference in categoric variables. The Kruskal-Wallis test was used to compare the difference in continuous variables. Statistically significant differences were assumed at a P value of less than 0.05.
RESULTS
Patients
From Table 1 .
At baseline, the groups were comparable in age, sex, pathologic types of thyroid cancer (papillary or follicular), and levels of thyroid-stimulating hormone at 131 I therapy.
Time-Activity Curves
Representative time-activity curves of the salivary glands are presented in Figure 2 .
Salivary Absorbed Dose 
Salivary Absorbed Dose During First 24 h After 131 I Ingestion
Salivary cumulated activities arising from the first 24 h after 131 I ingestion accounted for 86.08% 6 7.89% of total cumulated activities and ranged from 75% to 98% among patients ( Table 2 ). There was no significant difference in salivary absorbed dose during the first 24 h after 131 I ingestion among the 4 groups (Table 3) .
DISCUSSION
On the assumption that 131 I uptake by the salivary glands, just like thyroid tissue, would not plateau until 24 h after administration and that an early start of sour stimulation would further deliver 131 I by increased blood flow to the salivary glands, Nakada et al. (10) proposed that sour stimulation should not be initiated until 24 h after 131 I administration. Although the reported incidence of sialadenitis in the paper of Nakada et al. was higher in the earlycandy-sucking group (1 h after 131 I ingestion) than in the late-sucking group (24 h after 131 I ingestion) (64% and 37%, respectively, P , 0.05), 81% of the late-sucking group received ibuprofen or a steroid for radiation sialadenitis, versus 52% in the early-sucking group (10) (11) (12) (13) (14) . Whether this more aggressive treatment altered the outcome of the late-sucking group is unknown. Despite expressing sodium iodine symporters similar to those of thyroid tissue, salivary glands do not have thyroperoxidase and thus have an extremely short residence time of 131 I. The present study clearly showed that it is at 1-2 h after 131 I ingestion that uptake in the salivary glands is highest (Fig. 2) . Afterward, 131 I rapidly washes out from the glands. Little 131 I remains in the glands 24 h after ingestion. To determine the optimal regimen of sour stimulation, one should thus consider starting the sour stimulation at varied times, especially during the first 24 h after 131 I ingestion, and then observe if the salivary absorbed dose or the prevalence of salivary side effects changes.
Our study demonstrated that the start of vitamin C stimulation at various times after 131 I ingestion has little effect on salivary absorbed dose. The sour prescription of Nakada et al. (10) 
Neither prescription included nocturnal salivary gland stimulation. Because of ethical considerations, we did not set up a control group of patients who would not be given vitamin C stimulation at any time after 131 I ingestion. Salivary cumulated activities in the first 24 h after 131 I ingestion did, however, amount to 86.08% 6 7.89% (range, 75%298%) of total cumulated activities. As a result, salivary absorbed dose during the first 24 h accounted for a large proportion of total absorbed dose and may substitute for total absorbed dose; in addition, salivary absorbed dose during the first 24 h did not significantly differ among groups. Unlike patients in group D, all patients in groups A, B, and C had been given vitamin C stimulation in the first 24 h after 131 I ingestion. Group D can thus act as a control group. Therefore, the use of vitamin C stimulation at any time after 131 I ingestion has only a limited effect on salivary absorbed dose. The possible mechanisms underlying this finding follow:
Salivary glands have a high rate of metabolism and a high blood flow; both are proportional to the rate of saliva formation. The blood flow of the maximally secreting salivary gland is approximately 10 times that of an equal mass of actively contracting skeletal muscle (24, 25) . Color Doppler sonographic studies have shown that there is a close correlation between the increase in minimum velocity of the submandibular glands and that of saliva secretion after sour stimulation (26, 27) . In thyroid cancer patients, because 131 I uptake by the remnant thyroid tissue or metastatic thyroid cancer is much lower than that of normal thyroid tissue, and clearance of 131 I from the blood is substantially delayed because of a reduced glomerular filtration rate in the hypothyroid state, the blood concentration of 131 I early after 131 I ingestion is considerably high (28) . Therefore, sour stimulation not only can accelerate 131 I washout from the salivary glands by enhancing saliva flow but also can increase the amount of 131 I arriving at the glands by enhancing blood flow, which may partially or completely compensate for emptying effects. After sour stimulation, it can be postulated that, if the amount of 131 I secreted through increased saliva flow is greater than the amount arriving through increased blood flow, salivary absorbed dose would be reduced. In contrast, if the amount secreted is less than the amount arriving, salivary absorbed dose would be increased. However, if the amount secreted is equal or equivalent to the amount arriving-that is to say, the amount retained in the glands is balanced-then whether sour stimulation is given, and its timing, after 131 I ingestion would have little effect on salivary absorbed dose. Our study had strengths and limitations. First, to our knowledge, this was the first prospective, randomized, controlled dosimetry-based trial to investigate the effect of sour stimulation on the salivary glands. Salivary parenchymal functions and symptoms after 131 I therapy were not studied. Although it is accepted that radiation-absorbed dose to normal tissue in radionuclide therapy is able to predict toxicity (17) (18) (19) , investigations of the dose-effect relation for the salivary glands in 131 I therapy remain essential. Second, we investigated the effect of only the timing of salivary gland stimulation, and if the sour prescription in the study had been less stringent, the study would have been insufficiently powerful to detect the effect of sour stimulation on salivary absorbed dose. In view of the high incidence of salivary gland injury and the easy availability of sour stimulation, future controlled studies are needed to determine not only whether sour stimulation is necessary and when it is to be started but also how the dose and frequency are to be titrated. Third, it has become common practice in some areas to prepare thyroid cancer patients with recombinant human thyroid-stimulating hormone rather than traditional thyroid hormone withdrawal for 131 I therapy (9, 28, 29) . The optimal regimen of sour stimulation in that group is also worth investigating.
CONCLUSION
This prospective, randomized, single-blind, controlled study demonstrated that salivary stimulation with vitamin C at any time after 131 I administration has little effect on salivary absorbed dose in thyroid cancer patients. 
